MBX Biosciences' Phase 3 hypoparathyroidism trial enrolls, obesity pipeline advances
MBX said its pivotal canvuparatide trial is dosing patients, MBX 4291 data remain on track for Q4 2026, and cash on hand extends into 2029.
SEC filing, FDA (9)
4 stories
MBX said its pivotal canvuparatide trial is dosing patients, MBX 4291 data remain on track for Q4 2026, and cash on hand extends into 2029.
SEC filing, FDA (9)
The company said its PERFORMA Phase 3 MASH trial is progressing as planned and an FDA End-of-Phase 2 meeting for alcohol use disorder is set for December 2026.
SEC filing (2)
The company said it has FDA alignment on a registrational path for AATD drug WVE-006 and reported $431.0 million in cash as of September 30, 2026.
SEC filing (7)
The appointment, effective October 12, 2026, comes ahead of fourth-quarter topline data expected from Part 3 of the Phase 1 trial of DA-1726.
SEC filing